A US-Prospective, Registry-Based, Observational, Exposure Cohort Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population
Latest Information Update: 07 Mar 2024
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Acronyms OPERA-1
- Sponsors Incyte Corporation
Most Recent Events
- 19 Feb 2024 New trial record